Effects of the oral monophasic contraceptive pill CG 5025 (Belara/0,03 mg etinyl estradiol and 2 mg chlormadinonacetate) on the cosmetic hairquality in women wishing to use hormonal contraception

Trial Profile

Effects of the oral monophasic contraceptive pill CG 5025 (Belara/0,03 mg etinyl estradiol and 2 mg chlormadinonacetate) on the cosmetic hairquality in women wishing to use hormonal contraception

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Ethinylestradiol/chlormadinone (Primary)
  • Indications Pregnancy
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Nov 2012 Actual initiation date 25 Mar 2008 added as reported by EudraCT.
    • 02 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top